Gifts of the MAGI in Schizophrenia and Bipolar Disorder
New genetic findings reported in Biological Psychiatry
Philadelphia, PA, May 10, 2012 – These findings are not about the classic story of gift-giving, although the MAGI genes (officially named membrane associated guanylate kinase, WW and PDZ domain containing proteins) do influence brain function in important ways.
MAGI1 and MAGI2 are genes that code for the MAGI proteins. These proteins influence the development and function of synapses in the brain, the junctions where communication between nerve cells occurs.
Because they perform many important functions at brain synapses, researchers have made several attempts to tie these genes to psychiatric disease. So far, the efforts have been inconclusive, possibly because of insufficient statistical power, but now, authors of a new research study in Biological Psychiatry provide important evidence that MAGI1 and MAGI2 play a role in psychiatric disease.
Led by principal investigator and senior author Dr. Silvia Paddock, they examined genetic variations in families with bipolar affective disorder, schizophrenia, and schizoaffective disorder. These disorders have high overlapping genetic risk and are also highly heritable.
Using a multistage approach to assess and rank genetic variants, they identified rare mutations in MAGI1 and MAGI2.
Dr. John Krystal, Editor of Biological Psychiatry, commented, “We are searching for clues as to why the brain connections develop abnormally in people diagnosed with schizophrenia and bipolar disorder. In this case, the authors have found a very rare signal that may shed light on the cause of this problem for a small group of people carrying these diagnoses.”
“Our initial finding of mutated MAGI1 in a large, affected family may also indicate that it may have been premature by our field to declare linkage efforts failed,” Dr. Paddock noted. “Valuable samples from large families have already been collected and previous linkage results can guide us where to look for mutations. We can and should go back to these samples and analyze them with the unprecedented accuracy that today's technology has to offer."
The article is “MAGI1 Copy Number Variation in Bipolar Affective Disorder and Schizophrenia” by Robert Karlsson, Lisette Graae, Magnus Lekman, Dai Wang, Reyna Favis, Tomas Axelsson, Dagmar Galter, Andrea Carmine Belin, and Silvia Paddock (doi: 10.1016/j.biopsych.2012.01.020). The article appears in Biological Psychiatry, Volume 71, Issue 10 (May 15, 2012), published by Elsevier.
# # #
Notes for editors
Full text of the article is available to credentialed journalists upon request; contact Rhiannon Bugno at +1 214 648 0880 or Biol.Psych@utsouthwestern.edu. Journalists wishing to interview the authors may contact Dr. Silvia Paddock at +46 76 2805704 or firstname.lastname@example.org.
The authors’ affiliations, and disclosures of financial and conflicts of interests are available in the article.
John H. Krystal, M.D., is Chairman of the Department of Psychiatry at the Yale University School of Medicine and a research psychiatrist at the VA Connecticut Healthcare System. His disclosures of financial and conflicts of interests are available here.
About Biological Psychiatry
Biological Psychiatry is the official journal of the Society of Biological Psychiatry, whose purpose is to promote excellence in scientific research and education in fields that investigate the nature, causes, mechanisms and treatments of disorders of thought, emotion, or behavior. In accord with this mission, this peer-reviewed, rapid-publication, international journal publishes both basic and clinical contributions from all disciplines and research areas relevant to the pathophysiology and treatment of major psychiatric disorders.
The journal publishes novel results of original research which represent an important new lead or significant impact on the field, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Reviews and commentaries that focus on topics of current research and interest are also encouraged.
Biological Psychiatry is one of the most selective and highly cited journals in the field of psychiatric neuroscience. It is ranked 4th out of 126 Psychiatry titles and 15th out of 237 Neurosciences titles in the Journal Citations Reports® published by Thomson Reuters. The 2010 Impact Factor score for Biological Psychiatry is 8.674.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence,and ClinicalKey—and publishes over 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).Media contact
Editorial Office, Biological Psychiatry
+1 214 648 0880